U.S. Mortgage Finance Stock News

NYSE:BIO
NYSE:BIOLife Sciences

How Investors May Respond To Bio-Rad Laboratories (BIO) Facing Elliott’s Activist Push Over Sartorius Stake

On May 18, 2026, Elliott Investment Management disclosed a significant stake in Bio-Rad Laboratories and began pressing the company to address what it describes as prolonged share price underperformance since late 2021. A central focus of Elliott’s campaign is Bio-Rad’s multibillion-dollar ownership stake in Sartorius, which it argues could be used more effectively to enhance shareholder value. We’ll now look at how Elliott’s activist involvement, particularly around Bio-Rad’s Sartorius...
NasdaqGS:BIDU
NasdaqGS:BIDUInteractive Media and Services

Baidu’s AI Businesses Take Lead As Margins Lag And Apollo Grows

Baidu reports that its core AI powered businesses now account for more than half of general business revenue for the first time. The shift is linked to rapid progress in AI agents such as DuMate, Miaoda, Yijing, and Famou 2.0, along with a broader international rollout. Baidu’s autonomous ride hailing service, Apollo Go, has expanded to 27 cities, marking a wider commercial footprint in AI driven mobility. Baidu (NasdaqGS:BIDU) is trading at $127.79, with the stock up 52.5% over the past...
NYSE:ORCL
NYSE:ORCLSoftware

Will Oracle's New AI-Focused Cloud Deals and Samsung Java Alliance Change Oracle's (ORCL) Narrative

In May 2026, Oracle announced a string of developments including new healthcare and telecom partnerships, participation in an expanded beam optical connectivity alliance, a major Java standardization deal with Samsung, and the appointment of Cleveland Clinic CEO Dr. Tomislav Mihaljevic to its board. These moves collectively highlight Oracle’s push deeper into AI-ready cloud infrastructure and mission-critical industries, from semiconductor design to hospital systems and telecom...
NYSE:LNG
NYSE:LNGOil and Gas

Assessing Cheniere Energy (LNG) Valuation As Long Term Returns Outpace Recent Share Price Moves

Cheniere Energy (LNG) has drawn investor attention after recent price moves, with the stock roughly flat over the past day, lower over the past week and month, but higher over the past three months. See our latest analysis for Cheniere Energy. At a share price of $240.85, Cheniere Energy has a year to date share price return of 21.76%, while the 1 year total shareholder return of 6.15% contrasts with a much stronger 78.59% total shareholder return over three years. This suggests that long...
NasdaqGS:ALAB
NasdaqGS:ALABSemiconductor

Assessing Astera Labs (ALAB) Valuation After Analyst Upgrades And Jim Cramer Spotlight

Astera Labs stock in focus after upbeat commentary Astera Labs (ALAB) has moved into the spotlight after favorable analyst coverage and a positive mention from Jim Cramer, drawing fresh attention to its role in semiconductor and AI infrastructure. See our latest analysis for Astera Labs. The recent analyst endorsements and positive TV coverage have coincided with very strong trading momentum, with a 7 day share price return of 42.35% and a 90 day share price return of 139.00% pushing the...
NYSE:UDR
NYSE:UDRResidential REITs

Assessing UDR (UDR) Valuation As Recent Trading And Modest Undervaluation Signals Converge

How UDR stock has been trading recently UDR (UDR) has drawn investor attention after its recent share performance, with the stock last closing at US$38.01. Short term and longer term returns have varied, giving a mixed picture of momentum. See our latest analysis for UDR. Recent share price moves have been steady rather than dramatic, with a 1-month share price return of 9.32% and a 1-year total shareholder return of 0.91%. This suggests that momentum is still forming rather than fully...
NYSE:OHI
NYSE:OHIHealth Care REITs

Is It Too Late To Consider Omega Healthcare Investors (OHI) After Its Strong Multi Year Run?

Investors may be asking whether Omega Healthcare Investors at US$47.90 still offers value after a strong run, or if they might be late to the story. The stock is slightly down 0.9% over the past week, while returns sit at 3.2% over 30 days, 7.6% year to date, 40.8% over 1 year and 94.8% over 5 years. This mix often prompts investors to revisit what they are really paying for. Recent coverage has focused on Omega Healthcare Investors as a healthcare focused REIT, with attention on how its...
NasdaqGS:NDSN
NasdaqGS:NDSNMachinery

A Look At Nordson (NDSN) Valuation After Earnings Beat And Upgraded Outlook

Nordson (NDSN) has drawn fresh attention after reporting second quarter earnings and updating guidance, combining higher sales and earnings with increased full year and third quarter revenue expectations, supported by stronger backlog and order momentum. See our latest analysis for Nordson. The recent earnings beat and higher guidance appear to be feeding into sentiment, with Nordson’s share price up 4.75% over the past week and delivering a 52.01% 1 year total shareholder return, while the...
NYSE:NEE
NYSE:NEEElectric Utilities

U.S. Nuclear Reforms Test NextEra Energy Valuation And Growth Prospects

U.S. executive orders compress nuclear power permitting timelines and expand funding tools for new projects. The reforms are described as the most consequential governance change for the U.S. nuclear sector in decades. These shifts create new project and financing possibilities for large utilities, including NextEra Energy (NYSE:NEE). For investors following NextEra Energy (NYSE:NEE), the new U.S. nuclear policy framework directly intersects with the company’s role as a large regulated...
NasdaqGS:ADUS
NasdaqGS:ADUSHealthcare

What Does a Small Insider Sale Reveal About Addus HomeCare’s Regulatory Tailwind Story (ADUS)?

On May 19, 2026, Addus HomeCare director Esteban Lopez sold 250 shares of common stock in an open-market transaction at US$93.00 per share, leaving him with a remaining direct holding of roughly 3,200–3,450 shares disclosed in recent SEC Form 4 filings. At the same time, analysts highlight that Addus HomeCare may benefit from regulatory pressure on self-directed operators and an aging U.S. population, potentially widening its opportunity to acquire client books and grow its home-care...
NYSE:NYT
NYSE:NYTMedia

Is It Too Late To Consider New York Times (NYT) After Its Strong Multi Year Rally?

Wondering if New York Times stock at around US$74.96 is still offering value after a strong multi year run, or if most of the upside is already reflected in the price. The stock is up 7.4% year to date and 36.9% over the past year, although it has fallen 2.2% over the last week and is down 7.3% over the past month, which may have some investors reassessing the balance between upside and risk. Recent coverage has focused on New York Times as a long established media brand adapting to a...
NasdaqGS:MELI
NasdaqGS:MELIMultiline Retail

Linonia’s New MercadoLibre Stake Highlights Valuation Appeal And Margin Trade Offs

Linonia Partnership LP initiated a new stake in MercadoLibre during Q1, purchasing over $225 million in NasdaqGS:MELI shares. The move adds a fresh hedge fund investor to the shareholder base while MercadoLibre continues heavy spending on AI and cross-border commerce. This new position comes as investors focus on margin pressure and the trade off between reinvestment and near term profitability. MercadoLibre, traded as NasdaqGS:MELI, last closed at $1,664.42, with the stock up 5% over the...
NYSE:XPEV
NYSE:XPEVAuto

XPeng (NYSE:XPEV) Valuation After First Mass Produced Robotaxi Rollout In Guangzhou

XPeng (NYSE:XPEV) has moved its autonomous driving ambitions into commercial territory, officially rolling out China’s first mass produced, in house Robotaxi in Guangzhou, built on its GX platform and L4 pure vision system. See our latest analysis for XPeng. The Robotaxi launch comes as XPeng’s share price sits at US$15.59 and shorter term momentum has softened, with the stock down 23.69% year to date, even though the three year total shareholder return is up 90.12% while the five year total...
NasdaqGS:AVAV
NasdaqGS:AVAVAerospace & Defense

Assessing AeroVironment (AVAV) Valuation After New Autonomy Software And Defense Contract Momentum

AeroVironment (AVAV) is back in focus after unveiling AV Halo INSTINCT and DETECT, two new software modules aimed at autonomy and RF sensing for uncrewed systems in contested, multi-domain military environments. See our latest analysis for AeroVironment. Recent contract wins and AV Halo expansion come as the share price has been volatile, with a 1-day share price return of 6.83% but a year-to-date share price decline of 31.99%, while the 3-year total shareholder return is 88.72%. This...
NasdaqGS:MANH
NasdaqGS:MANHSoftware

What Manhattan Associates (MANH)'s New AI Suite and Exol Partnership Means For Shareholders

In May 2026, Manhattan Associates Inc. rolled out a suite of AI-focused upgrades, including Sightline explainable forecasting, the Solution Design Studio configuration workspace, and the Manhattan Marketplace ecosystem, while Exol announced it will deploy Manhattan’s warehouse and transportation platforms across its AI-enabled fulfillment network backed by a very large US$7,500 million commitment from SoftBank Group and Symbotic. Together, these moves push Manhattan’s platform deeper into...
NYSE:WAB
NYSE:WABMachinery

A Look At Wabtec (WAB) Valuation After Earnings Beat And Higher 2026 Guidance

Dividend decision and earnings guidance in focus Westinghouse Air Brake Technologies (WAB) recently reported first quarter results that exceeded analyst expectations and raised its adjusted 2026 earnings guidance, putting the stock back on the radar for investors tracking rail and industrial earnings. See our latest analysis for Westinghouse Air Brake Technologies. At a share price of $256.41, Wabtec has pulled back over the past month with a 30 day share price return of 3.99% and a 90 day...
NasdaqGS:JD
NasdaqGS:JDMultiline Retail

JD.com Weighs Very Group Deal As UK Push Raises New Questions

JD.com (NasdaqGS:JD) is reportedly exploring a potential acquisition of UK based online retailer The Very Group in a deal that could be valued at about £2b. The talks point to a shift in JD.com's overseas approach, moving from lighter partnership models to owning and operating a major e commerce player in the UK. The Very Group brings a recognised retail brand and consumer finance capabilities that could broaden JD.com's reach outside China. JD.com, trading at around $30.52, has had mixed...
NasdaqGS:IRDM
NasdaqGS:IRDMTelecom

Is It Too Late To Consider Iridium Communications (IRDM) After A 175% Year To Date Rally?

Wondering whether Iridium Communications at around US$48.84 is still offering value or if the easy gains are behind it? This article walks through what the current price might be implying about the stock. The share price has delivered returns of 12.5% over the past week, 25.4% over the past month, and 175.0% year to date, with a 1 year return of 99.0% but a 3 year decline of 14.1% and a 5 year return of 36.1%. Recent interest in Iridium Communications has been supported by ongoing attention...
NasdaqGS:JBLU
NasdaqGS:JBLUAirlines

Why JetBlue (JBLU) Is Up 10.3% After Deepening United Tie-Up and Launching Milan Route - And What's Next

Earlier in May 2026, JetBlue Airways and United Airlines announced expanded Blue Sky collaboration benefits, giving TrueBlue and MileagePlus members reciprocal elite-style perks plus integrated earning, redemption, and booking across both networks. At the same time, JetBlue launched its first-ever Italy route with daily Boston–Milan service, underscoring its push into higher-touch transatlantic flying while reinforcing its loyalty ecosystem. Next, we’ll examine how this deeper United...
NasdaqGS:CSIQ
NasdaqGS:CSIQSemiconductor

Canadian Solar (CSIQ) Is Up 9.9% After CEO Transition And Q2 Outlook Update Has The Bull Case Changed?

In May 2026, Canadian Solar Inc. reported first-quarter 2026 sales of US$1,077.88 million, a net loss of US$32.09 million, and announced a CEO transition with Colin Parkin succeeding founder Shawn Qu, who moved into Executive Chairman and Chief Technology Officer roles. The company also issued second-quarter 2026 guidance, forecasting US$1.0 billion to US$1.2 billion in revenue alongside specific targets for solar module and battery energy storage shipments, giving investors fresh insight...
NasdaqGS:ROIV
NasdaqGS:ROIVBiotechs

Roivant Shelf Plan Raises Questions On Dilution And Pipeline Funding

Roivant Sciences (NasdaqGS:ROIV) has filed a shelf registration that would allow it to issue nearly $1 billion in new common shares. The filing provides the company with flexibility to conduct future equity offerings when market conditions and funding needs align. This potential issuance could affect shareholder dilution, capital raising plans, and Roivant's ability to fund future projects. Roivant Sciences enters this development with its share price at $29.96 and very large multi-year...
NYSE:RBRK
NYSE:RBRKSoftware

Assessing Rubrik (RBRK) Valuation After MEDITECH Partnership And Upbeat BTIG Channel Feedback

Rubrik (RBRK) is back in focus after BTIG highlighted strong channel feedback and market share gains. This attention comes just days after Rubrik unveiled a new collaboration with healthcare IT provider MEDITECH. See our latest analysis for Rubrik. Rubrik’s recent MEDITECH partnership and upbeat BTIG channel checks come as the stock trades at US$66.59, with a 1 month share price return of 27.37% and a year to date share price decline of 11.77%. The 1 year total shareholder return is down...
NYSE:VZ
NYSE:VZTelecom

The Bull Case For Verizon (VZ) Could Change Following New Satellite JV And $4 Billion Note Sale - Learn Why

Earlier in May 2026, Verizon Communications closed the sale of US$2.00 billion each of 6.050% and 6.200% junior subordinated notes and, days later, joined AT&T and T-Mobile in announcing an agreement in principle for a joint venture to extend U.S. mobile coverage via satellite-based, direct-to-device technologies. This push into satellite-enabled connectivity, alongside fresh long-term funding, highlights Verizon’s effort to broaden network reach, support rural coverage, and create a shared...
NYSE:LLY
NYSE:LLYPharmaceuticals

A Look At Eli Lilly (LLY) Valuation After Retatrutide’s Strong Phase 3 Obesity Trial Results

Eli Lilly (LLY) is back in the spotlight after its investigational obesity drug retatrutide hit strong Phase 3 trial milestones, showing high and durable weight loss and sharpening investor focus on the company’s obesity franchise. See our latest analysis for Eli Lilly. The recent retatrutide headlines and broader cardiometabolic data have come alongside firm share price momentum, with a 1 month share price return of 20.48% and a 1 year total shareholder return of 50.28%. The year to date...